These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 520501)

  • 21. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors.
    Santiago M; Westerink BH
    Eur J Pharmacol; 1991 Oct; 204(1):79-85. PubMed ID: 1687125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effect of prolactin on dopamine release from the rat dorsal and ventral striatum and from the mediobasal hypothalamus superfused in vitro.
    Chen JC; Ramirez VD
    Eur J Pharmacol; 1988 Apr; 149(1-2):1-8. PubMed ID: 2456219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study of central dopaminergic properties of RU 29717 (N-propyl-9-oxaergoline) and pergolide.
    Boissier JR; Euvrard C; Oberlander C; Laurent J; Dumont C; Labrie F
    Eur J Pharmacol; 1983 Feb; 87(2-3):183-9. PubMed ID: 6857756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    Biochem Pharmacol; 1986 Jan; 35(2):143-4. PubMed ID: 3484628
    [No Abstract]   [Full Text] [Related]  

  • 25. Enhanced response to the inhibitory action of LY171555, a dopamine D2-agonist, on in vivo striatal dopamine release in DOCA/NaCl-hypertensive rats.
    Chen YF; Oparil S
    Brain Res; 1987 Jan; 400(2):225-31. PubMed ID: 2949797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of beta-endorphin on striatal dopamine metabolism.
    Van Loon GR; Kim C
    Res Commun Chem Pathol Pharmacol; 1977 Sep; 18(1):171-4. PubMed ID: 905630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of oestrus and ovulation with an ergoline derivative, substance VUFB 6638, an inhibitor of prolaction secretion.
    Ausková M; Rezábek K; Zikán V; Semonský M
    Physiol Bohemoslov; 1974; 23(5):417-21. PubMed ID: 4278534
    [No Abstract]   [Full Text] [Related]  

  • 28. Dopaminergic properties of mesulergine (CU 32-085) and its metabolites.
    Enz A; Donatsch P; Nordmann R
    J Neural Transm; 1984; 60(3-4):225-38. PubMed ID: 6527137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration of striatal tyramine and dopamine metabolism in diabetic rats and effect of insulin administration.
    Kwok RP; Juorio AV
    Neuroendocrinology; 1986; 43(5):590-6. PubMed ID: 3528901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the ergoline derivative VUFB-6683 on the adenohypophysial prolactin concentration in rats.
    Krejcí P; Ausková M; Rezábek K; Bílek J; Semonský M
    Experientia; 1973 Oct; 29(10):1262-3. PubMed ID: 4796640
    [No Abstract]   [Full Text] [Related]  

  • 31. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the mechanism of depletion of striatal dopamine by alpha-methyl-m-tyrosine.
    Uretsky NJ; Snodgrass SR; Lorenzo AV
    J Pharmacol Exp Ther; 1975 Dec; 195(3):465-79. PubMed ID: 490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of penfluridol on circling behavior and striatal DOPAC and serum prolactin concentrations in the rat.
    Annunziato LA; Wuerthele SM; Moore KE
    Eur J Pharmacol; 1978 Aug; 50(3):187-92. PubMed ID: 567584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of prolactin secretion in rats with the ergoline derivative deprenon.
    Chlebounová J; Seda M; Fingerová H; Rezábek K
    Arzneimittelforschung; 1980; 30(6):956-8. PubMed ID: 7191272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central dopamine agonist activity on the 8-alpha-amino-ergoline CU 32-085.
    Fuxe K; Agnati L; Mascagni F; Kuga S; Helmer-Matyjek E; Goldstein M
    Brain Res; 1985 Mar; 328(2):325-32. PubMed ID: 3986530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel 8 alpha-ergolines with inhibitory and stimulatory effects on prolactin secretion in rats.
    Wachtel H; Dorow R; Sauer G
    Life Sci; 1984 Oct; 35(18):1859-67. PubMed ID: 6492995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic administration of thyrotropin-releasing hormone enhances striatal dopamine release in vivo.
    Kreutz MR; Acworth IN; Lehnert H; Wurtman RJ
    Brain Res; 1990 Dec; 536(1-2):347-52. PubMed ID: 1707722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the mechanism of mergocryptine-induced suppression of dopamine turnover in the rat striatum.
    Hashimoto T; Katsura M; Kuriyama K
    Eur J Pharmacol; 1991 Jun; 198(2-3):121-7. PubMed ID: 1864302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.